ES2127730T3 - Secuencias de nucleotidos que codifican una proteina humana que tiene propiedades reguladoras de la angiogenesis. - Google Patents

Secuencias de nucleotidos que codifican una proteina humana que tiene propiedades reguladoras de la angiogenesis.

Info

Publication number
ES2127730T3
ES2127730T3 ES91916657T ES91916657T ES2127730T3 ES 2127730 T3 ES2127730 T3 ES 2127730T3 ES 91916657 T ES91916657 T ES 91916657T ES 91916657 T ES91916657 T ES 91916657T ES 2127730 T3 ES2127730 T3 ES 2127730T3
Authority
ES
Spain
Prior art keywords
angiogenesis
human protein
regulatory properties
nucleotide sequences
sequences coding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91916657T
Other languages
English (en)
Inventor
Maria Persico
Domenico Maglione
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Consiglio Nazionale delle Richerche
Original Assignee
Consiglio Nazionale delle Richerche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=11265849&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2127730(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Consiglio Nazionale delle Richerche filed Critical Consiglio Nazionale delle Richerche
Application granted granted Critical
Publication of ES2127730T3 publication Critical patent/ES2127730T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/515—Angiogenesic factors; Angiogenin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE PRESENTA UNA SECUENCIA DE CDNA QUE CODIFICA UNA PROTEINA HUMANA QUE TIENE PROPIEDADES REGULADORAS DE LA ANGIOGENESIS QUE HA SIDO AISLADA Y SECUENCIADA. EL VECTOR DE EXPRESION QUE CONTIENE DICHA SECUENCIA SE HA CONSTRUIDO Y, DESPUES DE LA TRANSFORMACION DE LAS CELULAS ANFITRIONAS, HA PODIDO OBTENERSE LA SINTESIS DE LA PROTEINA RELACIONADA. DICHA PROTEINA LLAMADA PIGF PUEDE EMPLEARSE TANTO EN EL CAMPO DE LA INMUNOLOGIA TUMORAL COMO EN EL DEL DIAGNOSTICO Y EN EL CAMPO TERAPEUTICO PARA LAS PATOLOGIAS RELACIONADAS CON LA FORMACION DE VASOS, COMO POR EJEMPLO LA CURACION DE LAS HERIDAS Y PROCESOS RELATIVOS.
ES91916657T 1990-09-27 1991-09-26 Secuencias de nucleotidos que codifican una proteina humana que tiene propiedades reguladoras de la angiogenesis. Expired - Lifetime ES2127730T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT48315A IT1242149B (it) 1990-09-27 1990-09-27 Sequenza di nucleotidi codificante per una proteina umana con proprieta' regolative dell'angiogenesi

Publications (1)

Publication Number Publication Date
ES2127730T3 true ES2127730T3 (es) 1999-05-01

Family

ID=11265849

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91916657T Expired - Lifetime ES2127730T3 (es) 1990-09-27 1991-09-26 Secuencias de nucleotidos que codifican una proteina humana que tiene propiedades reguladoras de la angiogenesis.

Country Status (10)

Country Link
US (1) US5919899A (es)
EP (1) EP0550519B1 (es)
JP (1) JP2987203B2 (es)
AT (1) ATE173505T1 (es)
AU (1) AU8635391A (es)
CA (1) CA2092533C (es)
DE (1) DE69130506T2 (es)
ES (1) ES2127730T3 (es)
IT (1) IT1242149B (es)
WO (1) WO1992006194A1 (es)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69229454T2 (de) * 1991-03-28 2000-01-05 Merck & Co., Inc. Untereinheit-C des vaskulären endothelialen Zellwachstumsfaktors
US7597886B2 (en) 1994-11-07 2009-10-06 Human Genome Sciences, Inc. Tumor necrosis factor-gamma
US7429646B1 (en) 1995-06-05 2008-09-30 Human Genome Sciences, Inc. Antibodies to human tumor necrosis factor receptor-like 2
US7964190B2 (en) 1996-03-22 2011-06-21 Human Genome Sciences, Inc. Methods and compositions for decreasing T-cell activity
US6635743B1 (en) 1996-03-22 2003-10-21 Human Genome Sciences, Inc. Apoptosis inducing molecule II and methods of use
WO1998027932A2 (en) * 1996-12-20 1998-07-02 Human Genome Sciences, Inc. Cerebellum and embryo specific protein
NZ500530A (en) * 1997-04-25 2001-12-21 Collateral Therapeutics Truncated VEGF-B, VEGF-C, VEGF-3, PlGF, VRF-2, poxvirus ORF-1 and ORF-2 proteins
WO2000050620A2 (en) 1999-02-26 2000-08-31 Human Genome Sciences, Inc. Human endokine alpha and methods of use
US20030022383A1 (en) * 1999-04-06 2003-01-30 Uab Research Foundation Method for screening crystallization conditions in solution crystal growth
US7727971B2 (en) * 2000-02-04 2010-06-01 Life Sciences Research Partners Vzw Use of placental growth factor for treating ischemic muscle disease
US7105168B1 (en) * 2002-06-04 2006-09-12 D. Collen Research Foundation Vzw Method of improving ischemic muscle function by administering placental growth factor
US6926898B2 (en) 2000-04-12 2005-08-09 Human Genome Sciences, Inc. Albumin fusion proteins
DK1297016T3 (da) * 2000-05-12 2006-07-10 Vlaams Interuniv Inst Biotech Anvendelse af placentavækstfaktorinhibitorer til behandling af patologisk angiogenese, patologisk arteriogenese, inflammation, tumordannelse og/eller vaskulær lækage
US7052705B2 (en) * 2001-10-03 2006-05-30 Regeneron Pharmaceuticals, Inc. Anti-angiogenic peptides
CA2841097A1 (en) 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Albumin and g-csf fusion proteins
JP4458850B2 (ja) * 2002-02-05 2010-04-28 ジェイモナト ソシエテ ペル アチオニ 組換え胎盤成長因子の製造方法
ITRM20020119A1 (it) 2002-03-05 2003-09-05 Geymonat Spa Composizioni contenenti plgf ad uso farmaceutico e cosmetico.
ITRM20020277A1 (it) * 2002-05-17 2003-11-17 Geymonat Spa Muteine del fattore di crescita placentare tipo 1, metodo di preparazione e loro applicazioni.
CA2509063C (en) 2002-11-16 2010-11-02 Dade Behring Marburg Gmbh Scd40l and placental growth factor (plgf) as biochemical marker combinations in cardiovascular diseases
US20060024302A1 (en) * 2004-03-05 2006-02-02 Ludwig Institute For Cancer Research Chimeric anti-VEGF-D antibodies and humanized anti-VEGF-D antibodies and methods of using same
US20050282233A1 (en) * 2004-03-05 2005-12-22 Ludwig Institute For Cancer Research Multivalent antibody materials and methods for VEGF/PDGF family of growth factors
NZ561763A (en) * 2005-03-24 2009-02-28 Thrombogenics Nv Novel anti PLGF antibody
DE102005022047A1 (de) 2005-05-09 2006-11-30 Dade Behring Marburg Gmbh Bindungspartner des Plazentalen Wachstumsfaktors insbesondere gegen den Plazentalen Wachstumsfaktor gerichtete Antikörper, ihre Herstellung und Verwendung
EP1904095B1 (en) * 2005-06-30 2013-05-29 VIB, vzw Treatment of liver cirrhosis and its complications
AU2006267097A1 (en) * 2005-07-13 2007-01-18 Beth Israel Deaconess Medical Center Methods of diagnosing and treating an inflammatory response
ES2363758T3 (es) * 2005-08-15 2011-08-16 Vegenics Pty Ltd Vegf y pdgf modificados con propiedades angiogénicas mejoradas.
ES2429225T3 (es) 2006-05-17 2013-11-13 The Ludwig Institute For Cancer Research Anticuerpos anti VEGF-B para tratamiento o profilaxis de diabetes de tipo II o síndrome metabólico
NZ586544A (en) 2007-12-26 2012-07-27 Vaccinex Inc Anti-c35 antibody in combination with an ani-her2 antibody in cancer therapies and methods
CN101918834B (zh) 2008-01-07 2014-05-28 奥索临床诊断有限公司 用于同时分析能够彼此络合的蛋白质的校准物/对照物
US8741287B2 (en) 2008-06-18 2014-06-03 Abbott Laboratories PlGF-1 assay and kits and components thereof
US20100004306A1 (en) * 2008-06-18 2010-01-07 Abbott Laboratories PIGF-1 Assay and kits and components thereof
WO2010037864A2 (en) 2008-10-02 2010-04-08 Vib Vzw Inhibition of plgf to treat philadelphia chromosome positive leukemia
EP2295449A1 (en) 2009-09-09 2011-03-16 Dompe PHA.R.MA S.p.A. PLGF-1 in homodimeric form
CN103087153B (zh) * 2011-10-28 2015-05-06 上海市第一人民医院 一类新的抑制新生血管的小肽及其应用
EP2785739B1 (en) 2011-12-01 2017-03-15 ThromboGenics N.V. Improving trabeculectomy outcome
WO2014055849A1 (en) 2012-10-05 2014-04-10 Alere San Diego, Inc. Methods for diagnosing and prognosing placental dysfunction and pre-eclampsia
CN116437941A (zh) * 2020-09-29 2023-07-14 Cefo有限公司 包含plgf的用于预防或治疗神经精神性疾病的组合物

Also Published As

Publication number Publication date
IT9048315A1 (it) 1992-03-27
EP0550519B1 (en) 1998-11-18
US5919899A (en) 1999-07-06
CA2092533C (en) 2002-05-28
IT1242149B (it) 1994-02-16
DE69130506D1 (de) 1998-12-24
JPH06503225A (ja) 1994-04-14
EP0550519A1 (en) 1993-07-14
WO1992006194A1 (en) 1992-04-16
CA2092533A1 (en) 1992-03-28
AU8635391A (en) 1992-04-28
JP2987203B2 (ja) 1999-12-06
DE69130506T2 (de) 1999-06-24
IT9048315A0 (it) 1990-09-27
ATE173505T1 (de) 1998-12-15

Similar Documents

Publication Publication Date Title
ES2150916T3 (es) Utilizacion del acido gentisico o del alcohol gentisilico para estabilizar peptidos y proteinas radiomarcados.
ES8703490A1 (es) Un procedimiento para producir un polipeptido que tiene o contiene un polipeptido de factor de necrosis de tumor humano
IT1210364B (it) Bisturi chirurgico del tipo criogenico ad ultrasuoni.
CA2092533A1 (en) Nucleotide sequences coding for a human protein with angiogenesis regulative properties
ES8801671A1 (es) Un procedimiento para preparar relaxina humana o sus analogos
ES2068791T1 (es) Metodos y acido desoxirribonucleico para la preparacion de proteina de factor de tejido.
DE3683482D1 (de) Cdns und gen fuer menschliches angiogenin (angiogenesis-faktor) und expression.
SE9401091D0 (sv) Alphavirus cDNA vectors
DK43890A (da) Nucleinsyre, vektorer og celler indeholdende den, derudfra fremstillede produkter og disses anvendelse
NO953699D0 (no) Isolerte nukleinsyremolekyler som koder for tumor-rejeksjonsforlöperen MAGE-3, samt anvendelser derav
ES2061632T3 (es) Kluyveromyces como celula hospedante.
ES2130120T3 (es) Procedimiento para la preparacion de la adnasa humana.
ES8801675A1 (es) Un procedimiento para preparar relaxina-h2 humana
NO873699D0 (no) Polypeptid som er egnet til dempning, behandling og diagnosering av autoimmune lidelser saasom leddbetennelser.
ZA814607B (en) 2-pohenyl-1,2-benzisoselelenazol-3(2h)-one containing pharmaceutical preparations and their use
ES2177636T3 (es) Utilizacion del agua empobrecida en deuterio en la preparacion de cosmeticos.
ES2042749T3 (es) Producto para el tratamiento del cabello.
ES2052583T3 (es) Derivados de peptidos relacionados con el gel calcitonina.
ES2087869T3 (es) Proteinas modificadas; interferones alfa y beta modificados, proteinas fosforiladas y analogos, secuencias de adn, y sus aplicaciones.
ES2012940A6 (es) Un procedimiento para la preparacion de una celula de mamifero capaz de expresar interleukin-2 humana.
ES2059436T3 (es) Proteina de la membrana exterior f de pseudomonas aeruginosa.
ES2169503T3 (es) Polisacaridos bacterianos orto-sulfatados.
AR246310A1 (es) Procedimiento para la preparacion de la cadena alfa- del receptor de la interleucina 5 humana, o partes del mismo, secuencia del adn, vector y celula hospedante.
FI863626A0 (fi) Dna-sekvenser, rekombinant-dna -molekyler och foerfaranden foer framstaellning av polypeptider som liknar humant lipokortin.
DE69225706D1 (de) Humanes galanin, cdna-klone die für humanes galanin kodieren und eine methode humanes galamin herzustellen

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 550519

Country of ref document: ES